Development asset linked to Agomab Therapeutics NV in public FDA and regional records.
biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
AGMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
Agomab Therapeutics NV pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Agomab Therapeutics NV drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Agomab Therapeutics NV in public FDA and regional records.